Navigation Links
Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/29/2012

PHILADELPHIA, May 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics will present at the Jefferies 2012 Global Healthcare Conference.

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors at 11:00 AM ET on Tuesday, June 5th in New York City.  

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... be participating in the Morgan Stanley 2014 Global Healthcare ... York, New York , on Tuesday, September 9, ... Zimmer, will be presenting at 9:10 a.m. Eastern Time.  ... will join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... Malaysia , Aug. 27, 2014 ... health insurance are fuelling the demand for medical ... the rise of medical tourism, the inflow of ... increasing. The market will continue its steady ascent ... to age-related and non-communicable diseases, compelling significant investments ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the Simply ... about the importance of capacity to grow a business. , ... and is now a 5 Star Ambassador, Vi Millionaire, and ... titled "The Playful and Powerful Warrior Within You!" and holds ... out for over 1000 days straight. He is also ...
(Date:8/27/2014)... York, NY (PRWEB) August 27, 2014 Overcoming ... failure, he finally found his niche. The Women’s Radio Network, ... Armstrong for his continued support and dedication to the WRNW1 ... be able to have such a positive atmosphere.” After KC ... on Sirius XM of the Howard Stern show, “Howard 100 ...
(Date:8/27/2014)... 2014 A recently published study ... of time in correcting coagulopathy to prevent permanent injury ... of anticoagulants and examines medical conditions alleged to be ... although anticoagulants have been approved by the FDA to ... are also known to affect the consistency of the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The use ... quality of life and may eliminate the need for ... During a recent AllMed webinar, Dr. Zanhua Yi, board ... related to determining medical necessity of erythropoiesis-stimulating agents (ESAs) ... (CKD). , The U.S. Food and Drug Administration (FDA) ...
(Date:8/27/2014)... August 27, 2014 iHire was ... as the “Most Creative Workplace” in Frederick, a ... Places to Work Awards. , Held at the ... is a joint partnership between the Frederick County ... Development, Frederick County Business Development and Retention, and ...
Breaking Medicine News(10 mins):Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:iHire Named Most Creative Workplace in Frederick, MD 2
... March 3, 2008 The International AIDS Vaccine Initiative ... Fund, a new funding mechanism that will identify and ... AIDS vaccine research field. This initial project will apply ... the size of a small coin, which has the ...
... a new genetic risk factor for coeliac disease, have, ... implicated in causing the condition. The team, lead by ... and The London School of Medicine and Dentistry, have ... now know, four of these are also predisposing factors ...
... March 2 Therap Services announces the,release of version ... applications. Therap version 7.2 will feature,new forms such as ... module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) form in ... 7.2 include: -- Behavior Plan and Behavior Event ...
... Incontinence, dropped organs not just a function of age, study ... women in the United States have one or more pelvic ... disorders, says a Kaiser Permanente study. , Frequent urge to ... of such disorders. , The study of 4,000 women (80 ...
... Md. and ST. PAUL, Minn., Feb. 29 /PRNewswire-USNewswire/,-- ... Society &,Family Services, application for full Hague Accreditation ... This achievement of Hague,Accreditation demonstrates CHSFS, commitment to ... and abroad., The Hague Convention on Protection ...
... OAKLAND, Calif., Feb. 29 California,s,largest nonprofit hospital ... negotiations Thursday covering 15,000 hospital,workers across California., ... of negotiations underway and,continue their joint efforts to ... services across the state. In 2004, Catholic Healthcare,West ...
Cached Medicine News:Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Scientists uncover further steps leading to celiac disease 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:Pelvic Floor Disorders Affect 1 in 3 Women 2Health News:Children's Home Society & Family Services Achieves Full Hague Accreditation 2Health News:Catholic Healthcare West and SEIU Begin Negotiations for 15,000 Hospital Workers 2
Inquire...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
Medicine Products: